Annual CFO
-$27.79 M
-$3.55 M-14.63%
30 September 2023
Summary:
Anavex Life Sciences annual cash flow from operations is currently -$27.79 million, with the most recent change of -$3.55 million (-14.63%) on 30 September 2023. During the last 3 years, it has risen by +$2.60 million (+8.55%). AVXL annual CFO is now -233387.39% below its all-time high of -$11.90 thousand, reached on 30 September 2004.AVXL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$5.18 M
+$6.48 M+55.56%
30 June 2024
Summary:
Anavex Life Sciences quarterly cash flow from operations is currently -$5.18 million, with the most recent change of +$6.48 million (+55.56%) on 30 June 2024. Over the past year, it has increased by +$669.00 thousand (+11.44%). AVXL quarterly CFO is now -19214.39% below its all-time high of $27.10 thousand, reached on 30 June 2006.AVXL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$30.00 M
+$2.47 M+7.61%
30 June 2024
Summary:
Anavex Life Sciences TTM cash flow from operations is currently -$30.00 million, with the most recent change of +$2.47 million (+7.61%) on 30 June 2024. Over the past year, it has dropped by -$2.22 million (-7.98%). AVXL TTM CFO is now -2727445.45% below its all-time high of -$1100.00, reached on 31 December 2004.AVXL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVXL Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +11.4% | -8.0% |
| 3 y3 years | +8.6% | +32.5% | +1.3% |
| 5 y5 years | -50.0% | -104.4% | -61.9% |
AVXL Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.6% | +8.6% | -48.0% | +55.6% | -23.8% | +7.6% |
| 5 y | 5 years | -50.0% | +8.6% | -104.4% | +55.6% | -70.8% | +7.6% |
| alltime | all time | <-9999.0% | +8.6% | <-9999.0% | +55.6% | <-9999.0% | +7.6% |
Anavex Life Sciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$5.18 M(-55.6%) | -$30.00 M(-7.6%) |
| Mar 2024 | - | -$11.66 M(+59.3%) | -$32.48 M(+10.8%) |
| Dec 2023 | - | -$7.32 M(+25.1%) | -$29.31 M(+5.5%) |
| Sept 2023 | -$27.79 M(+14.6%) | -$5.85 M(-23.6%) | -$27.79 M(+6.9%) |
| June 2023 | - | -$7.65 M(-9.8%) | -$25.98 M(+2.4%) |
| Mar 2023 | - | -$8.49 M(+46.5%) | -$25.38 M(-4.3%) |
| Dec 2022 | - | -$5.79 M(+43.3%) | -$26.53 M(+9.5%) |
| Sept 2022 | -$24.24 M(-20.2%) | -$4.04 M(-42.7%) | -$24.24 M(-13.0%) |
| June 2022 | - | -$7.05 M(-26.8%) | -$27.87 M(-1.6%) |
| Mar 2022 | - | -$9.64 M(+175.3%) | -$28.34 M(+8.9%) |
| Dec 2021 | - | -$3.50 M(-54.4%) | -$26.01 M(-14.4%) |
| Sept 2021 | -$30.38 M(+42.7%) | -$7.67 M(+2.0%) | -$30.38 M(+4.9%) |
| June 2021 | - | -$7.52 M(+2.8%) | -$28.96 M(+13.6%) |
| Mar 2021 | - | -$7.32 M(-7.0%) | -$25.49 M(+8.8%) |
| Dec 2020 | - | -$7.87 M(+25.8%) | -$23.43 M(+10.1%) |
| Sept 2020 | -$21.29 M(+14.9%) | -$6.25 M(+54.7%) | -$21.29 M(+21.2%) |
| June 2020 | - | -$4.04 M(-23.2%) | -$17.57 M(-16.4%) |
| Mar 2020 | - | -$5.26 M(-8.1%) | -$21.02 M(+4.6%) |
| Dec 2019 | - | -$5.73 M(+125.9%) | -$20.09 M(+8.4%) |
| Sept 2019 | -$18.53 M(+47.2%) | -$2.53 M(-66.2%) | -$18.53 M(-7.6%) |
| June 2019 | - | -$7.50 M(+73.2%) | -$20.05 M(+37.0%) |
| Mar 2019 | - | -$4.33 M(+4.1%) | -$14.63 M(+11.5%) |
| Dec 2018 | - | -$4.16 M(+2.6%) | -$13.12 M(+4.3%) |
| Sept 2018 | -$12.58 M(+39.5%) | -$4.05 M(+94.1%) | -$12.58 M(+17.4%) |
| June 2018 | - | -$2.09 M(-26.0%) | -$10.72 M(-7.6%) |
| Mar 2018 | - | -$2.82 M(-22.1%) | -$11.61 M(+22.4%) |
| Dec 2017 | - | -$3.62 M(+65.2%) | -$9.48 M(+5.2%) |
| Sept 2017 | -$9.02 M(-2.4%) | -$2.19 M(-26.3%) | -$9.02 M(+3.8%) |
| June 2017 | - | -$2.97 M(+326.3%) | -$8.69 M(+9.5%) |
| Mar 2017 | - | -$697.70 K(-77.9%) | -$7.94 M(-13.2%) |
| Dec 2016 | - | -$3.15 M(+69.2%) | -$9.14 M(-1.0%) |
| Sept 2016 | -$9.24 M(+118.5%) | -$1.86 M(-16.2%) | -$9.24 M(+4.9%) |
| June 2016 | - | -$2.22 M(+16.9%) | -$8.81 M(+9.9%) |
| Mar 2016 | - | -$1.90 M(-41.4%) | -$8.01 M(+18.2%) |
| Dec 2015 | - | -$3.25 M(+126.5%) | -$6.78 M(+60.4%) |
| Sept 2015 | -$4.23 M(+58.9%) | -$1.43 M(+0.2%) | -$4.23 M(+13.9%) |
| June 2015 | - | -$1.43 M(+113.4%) | -$3.71 M(+14.5%) |
| Mar 2015 | - | -$670.30 K(-3.3%) | -$3.24 M(+11.1%) |
| Dec 2014 | - | -$693.10 K(-24.4%) | -$2.92 M(+9.7%) |
| Sept 2014 | -$2.66 M | -$916.90 K(-4.5%) | -$2.66 M(+19.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2014 | - | -$960.00 K(+176.3%) | -$2.23 M(+71.4%) |
| Mar 2014 | - | -$347.50 K(-20.1%) | -$1.30 M(+20.2%) |
| Dec 2013 | - | -$435.00 K(-10.2%) | -$1.08 M(+39.0%) |
| Sept 2013 | -$777.60 K(-54.1%) | -$484.50 K(+1404.7%) | -$777.60 K(+42.7%) |
| June 2013 | - | -$32.20 K(-75.1%) | -$545.00 K(-27.5%) |
| Mar 2013 | - | -$129.30 K(-1.7%) | -$751.50 K(+2.1%) |
| Dec 2012 | - | -$131.60 K(-47.8%) | -$736.40 K(-56.5%) |
| Sept 2012 | -$1.69 M(-55.5%) | -$251.90 K(+5.5%) | -$1.69 M(-28.4%) |
| June 2012 | - | -$238.70 K(+109.0%) | -$2.36 M(-29.0%) |
| Mar 2012 | - | -$114.20 K(-89.5%) | -$3.33 M(-12.5%) |
| Dec 2011 | - | -$1.09 M(+17.9%) | -$3.81 M(+0.1%) |
| Sept 2011 | -$3.80 M(-17.2%) | -$922.60 K(-23.5%) | -$3.80 M(-16.3%) |
| June 2011 | - | -$1.21 M(+104.8%) | -$4.54 M(+2.4%) |
| Mar 2011 | - | -$588.90 K(-45.7%) | -$4.44 M(-9.4%) |
| Dec 2010 | - | -$1.08 M(-34.8%) | -$4.90 M(+6.6%) |
| Sept 2010 | -$4.59 M(+64.4%) | -$1.66 M(+51.4%) | -$4.59 M(+17.7%) |
| June 2010 | - | -$1.10 M(+4.6%) | -$3.90 M(-2.1%) |
| Mar 2010 | - | -$1.05 M(+34.7%) | -$3.98 M(+20.5%) |
| Dec 2009 | - | -$780.00 K(-19.7%) | -$3.31 M(+18.3%) |
| Sept 2009 | -$2.79 M(+13.0%) | -$971.30 K(-17.8%) | -$2.79 M(+8.0%) |
| June 2009 | - | -$1.18 M(+216.2%) | -$2.59 M(+29.1%) |
| Mar 2009 | - | -$373.60 K(+39.2%) | -$2.00 M(-3.0%) |
| Dec 2008 | - | -$268.30 K(-64.9%) | -$2.07 M(-16.5%) |
| Sept 2008 | -$2.47 M(+660.8%) | -$764.50 K(+27.9%) | -$2.47 M(+39.8%) |
| June 2008 | - | -$597.60 K(+37.2%) | -$1.77 M(+28.7%) |
| Mar 2008 | - | -$435.60 K(-35.6%) | -$1.38 M(+38.3%) |
| Dec 2007 | - | -$676.40 K(+1025.5%) | -$993.90 K(+205.5%) |
| Sept 2007 | -$325.20 K(+903.7%) | -$60.10 K(-70.4%) | -$325.30 K(+6.1%) |
| June 2007 | - | -$202.90 K(+272.3%) | -$306.50 K(+300.7%) |
| Mar 2007 | - | -$54.50 K(+598.7%) | -$76.50 K(+95.2%) |
| Dec 2006 | - | -$7800.00(-81.1%) | -$39.20 K(+20.6%) |
| Sept 2006 | -$32.40 K(-47.0%) | -$41.30 K(-252.4%) | -$32.50 K(+177.8%) |
| June 2006 | - | $27.10 K(-257.6%) | -$11.70 K(-69.8%) |
| Mar 2006 | - | -$17.20 K(+1463.6%) | -$38.80 K(-36.4%) |
| Dec 2005 | - | -$1100.00(-94.6%) | -$61.00 K(0.0%) |
| Sept 2005 | -$61.10 K(+413.4%) | -$20.50 K(<-9900.0%) | -$61.00 K(+50.6%) |
| June 2005 | - | $0.00(-100.0%) | -$40.50 K(0.0%) |
| Mar 2005 | - | -$39.40 K(+3481.8%) | -$40.50 K(+3581.8%) |
| Dec 2004 | - | -$1100.00 | -$1100.00 |
| Sept 2004 | -$11.90 K | - | - |
FAQ
- What is Anavex Life Sciences annual cash flow from operations?
- What is the all time high annual CFO for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly CFO year-on-year change?
- What is Anavex Life Sciences TTM cash flow from operations?
- What is the all time high TTM CFO for Anavex Life Sciences?
- What is Anavex Life Sciences TTM CFO year-on-year change?
What is Anavex Life Sciences annual cash flow from operations?
The current annual CFO of AVXL is -$27.79 M
What is the all time high annual CFO for Anavex Life Sciences?
Anavex Life Sciences all-time high annual cash flow from operations is -$11.90 K
What is Anavex Life Sciences quarterly cash flow from operations?
The current quarterly CFO of AVXL is -$5.18 M
What is the all time high quarterly CFO for Anavex Life Sciences?
Anavex Life Sciences all-time high quarterly cash flow from operations is $27.10 K
What is Anavex Life Sciences quarterly CFO year-on-year change?
Over the past year, AVXL quarterly cash flow from operations has changed by +$669.00 K (+11.44%)
What is Anavex Life Sciences TTM cash flow from operations?
The current TTM CFO of AVXL is -$30.00 M
What is the all time high TTM CFO for Anavex Life Sciences?
Anavex Life Sciences all-time high TTM cash flow from operations is -$1100.00
What is Anavex Life Sciences TTM CFO year-on-year change?
Over the past year, AVXL TTM cash flow from operations has changed by -$2.22 M (-7.98%)